Maria Angeles
Florez Menendez
![Foto de Maria Angeles](/img/nophoto.png)
![Foto de Hospital Universitari de Bellvitge](/img/noimage_org.png)
Hospital Universitari de Bellvitge
l'Hospitalet de Llobregat, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitari de Bellvitge (10)
2024
-
[Translated article] Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 3, pp. T237-T245
2023
-
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 1, pp. 57-64
-
Clinical Approach to Patients with Moderate-to-Severe Atopic Dermatitis: A Spanish Delphi Consensus
Acta Dermato-Venereologica, Vol. 103
-
Observational 24-week study to assess clinical response to upadacitinib posttrial in patients with moderate-to-severe atopic dermatitis
JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 571-575
-
Primary Cutaneous Lymphoma Registry of the Spanish Academy of Dermatology and Venereology (AEDV): Data for the First 5 Years
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 291-298
-
Real-World Experience with Vismodegib on Advanced and Multiple BCCs: Data from the RELIVIS Study
Dermatology (Basel, Switzerland), Vol. 239, Núm. 5, pp. 685-693
-
Requirements for Accessing New Dermatology Drugs in Spain: Results of the EQUIDAD Study
Actas Dermo-Sifiliograficas
-
Sonidegib as a Locally Advanced Basal Cell Carcinoma Therapy in Real-life Clinical Setting: A National Multicentre Study
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 7, pp. T565-T571
2020
-
Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Journal of the American Academy of Dermatology, Vol. 83, Núm. 5, pp. 1535-1538
2018
-
The First Year of the AEVD Primary Cutaneous Lymphoma Registry
Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 610-616